Subcutaneous versus intravenous bortezomib: Efficiency practice variables and patient preferences

Annals of Pharmacotherapy

Volumn 47, Issue 9, 2013, Pages 1136-1142

  Barbee, Meagan S ^a,b   Donald Harvey, R ^c   Lonial, Sagar ^c   Kaufman, Jonathan L ^c   Wilson, Nicole M ^b,c   McKibbin, Trevor ^b,c   Hutcherson, Donald A ^b,c   Surati, Minal ^c   Valla, Kelly ^c   Shah, Katherine Sanvidge ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCER UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Administration route; Bortezomib; Efficiency; Multiple myeloma; Preference; Quality of life; Satisfaction; Subcutaneous

Indexed keywords

BORTEZOMIB;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE MYELOMA; PATIENT PREFERENCE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY;

ADMINISTRATION ROUTE; BORTEZOMIB; EFFICIENCY; MULTIPLE MYELOMA; PREFERENCE; QUALITY OF LIFE; SATISFACTION; SUBCUTANEOUS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PATIENT PREFERENCE; PYRAZINES;

EID: 84884473847     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013503122     Document Type: Article

References (22)

1. Erikson C, Salsberg E, Forte G, et al. Future supply and demand for oncologists: challenges to assuring access to oncology services. J Oncol Pract 2007;3:79-86.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111: 2516-20.
3. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2009 (vintage 2009 populations), National Cancer Institute. Bethesda, MD. http://seer.cancer. gov/csr/1975_2009_pops09/(accessed 2012 Nov 1).
4. Goodin HJ. The nursing shortage in the United States of America: an integrative review of the literature. J Adv Nurs 2003;43:335-45.
5. Beurhaus P, Donelan K, DesRoches C, Lamkin L, Mallory G. State of the oncology nursing workforce: problems and implications for strengthening the future. Nursing Econ 2001;19:1-11
6. Anderson KC, Alsina M, Bensinger W, et al. NCCN Clinical Practice Guidelines in Oncology. Multiple myeloma. V.2. 2013. www.nccn.org (accessed 2013 Apr 21).
7. Product information. Velcade (bortezomib). Cambridge, MA: Millennium Pharmaceuticals, Inc., October 2012.
8. Moreau P, Coiteux V, Hulin C, et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 2008;93:1908-11.
9. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431-40.
10. Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012; 97:1925-8.
11. Mateos MV. Subcutaneous bortezomib: a step towards optimised drug use. Lancet Oncol 2011;12:410-1.
12. Lonial S. Is subcutaneous bortezomib ready for prime time? Curr Hematol Malig Rep 2011;6:73-4.
13. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomibinduced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112: 1593-9.
14. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-20.
15. Allen PB, Lindsay H, Tham TCK. How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol 2010;10:1. doi: 10.1186/1471-230X-10-1
16. Scarpato S, Antivalle M, Favalli EG, et al. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford) 2010; 49:289-94.
17. Lalezari JP, Saag M, Walworth C, et al. An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-Label Safety Study (BOSS). AIDS Res Human Retroviruses 2008;24:805-13.
18. Coulter A, Entwistle V, Gilbert D. Sharing decisions with patients: is the information good enough? BMJ 1999;318: 318-22.
19. Kamimura T, Miyamoto T, Yokota N, et al. Higher incidence of injections site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen. Eu J Haematol 2012;90:157-61.
20. Obeid KM, Ferrara R, Sharma M. Cutaneous lesion induced by a subcutaneous administration of bortezomib. Clin Lymphoma Myeloma Leuk 2012;4:284-6.
21. Mateos M-V, San Muigues JF. Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeoma. Ther Adv Hematol 2012;2:117-24.
22. Moreau P, Karamanesht I, Domnikova N, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet 2012;51:823-9.